COLL Relative Valuation
COLL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COLL is overvalued; if below, it's undervalued.
Historical Valuation
Collegium Pharmaceutical Inc (COLL) is now in the Undervalued zone, suggesting that its current forward PE ratio of 6.35 is considered Undervalued compared with the five-year average of 4.65. The fair price of Collegium Pharmaceutical Inc (COLL) is between 125.22 to 137.51 according to relative valuation methord. Compared to the current price of 47.53 USD , Collegium Pharmaceutical Inc is Undervalued By 62.04%.
Relative Value
Fair Zone
125.22-137.51
Current Price：47.53
62.04%
Undervalued
6.30
PE
1Y
3Y
5Y
Trailing
Forward
4.52
EV/EBITDA
Collegium Pharmaceutical Inc. (COLL) has a current EV/EBITDA of 4.52. The 5-year average EV/EBITDA is 3.97. The thresholds are as follows: Strongly Undervalued below 2.59, Undervalued between 2.59 and 3.28, Fairly Valued between 4.66 and 3.28, Overvalued between 4.66 and 5.35, and Strongly Overvalued above 5.35. The current Forward EV/EBITDA of 4.52 falls within the Historic Trend Line -Fairly Valued range.
10.39
EV/EBIT
Collegium Pharmaceutical Inc. (COLL) has a current EV/EBIT of 10.39. The 5-year average EV/EBIT is 9.63. The thresholds are as follows: Strongly Undervalued below 3.96, Undervalued between 3.96 and 6.79, Fairly Valued between 12.46 and 6.79, Overvalued between 12.46 and 15.29, and Strongly Overvalued above 15.29. The current Forward EV/EBIT of 10.39 falls within the Historic Trend Line -Fairly Valued range.
1.89
PS
Collegium Pharmaceutical Inc. (COLL) has a current PS of 1.89. The 5-year average PS is 1.60. The thresholds are as follows: Strongly Undervalued below 0.81, Undervalued between 0.81 and 1.20, Fairly Valued between 1.99 and 1.20, Overvalued between 1.99 and 2.39, and Strongly Overvalued above 2.39. The current Forward PS of 1.89 falls within the Historic Trend Line -Fairly Valued range.
3.82
P/OCF
Collegium Pharmaceutical Inc. (COLL) has a current P/OCF of 3.82. The 5-year average P/OCF is 3.62. The thresholds are as follows: Strongly Undervalued below 1.37, Undervalued between 1.37 and 2.49, Fairly Valued between 4.74 and 2.49, Overvalued between 4.74 and 5.86, and Strongly Overvalued above 5.86. The current Forward P/OCF of 3.82 falls within the Historic Trend Line -Fairly Valued range.
3.83
P/FCF
Collegium Pharmaceutical Inc. (COLL) has a current P/FCF of 3.83. The 5-year average P/FCF is 2.66. The thresholds are as follows: Strongly Undervalued below -2.59, Undervalued between -2.59 and 0.03, Fairly Valued between 5.29 and 0.03, Overvalued between 5.29 and 7.92, and Strongly Overvalued above 7.92. The current Forward P/FCF of 3.83 falls within the Historic Trend Line -Fairly Valued range.
Collegium Pharmaceutical Inc (COLL) has a current Price-to-Book (P/B) ratio of 5.50. Compared to its 3-year average P/B ratio of 4.63 , the current P/B ratio is approximately 18.76% higher. Relative to its 5-year average P/B ratio of 4.15, the current P/B ratio is about 32.66% higher. Collegium Pharmaceutical Inc (COLL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 23.00%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 18.88% , the current FCF yield is about -100.00% lower.
5.45
P/B
Median3y
4.63
Median5y
4.15
19.13
FCF Yield
Median3y
23.00
Median5y
18.88
Competitors Valuation Multiple
The average P/S ratio for COLL's competitors is 0.00, providing a benchmark for relative valuation. Collegium Pharmaceutical Inc Corp (COLL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 31.42%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of COLL increased by 65.55% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 5.86 to 15.05.
The secondary factor is the Revenue Growth, contributed 31.42%to the performance.
Overall, the performance of COLL in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Collegium Pharmaceutical Inc (COLL) currently overvalued or undervalued?
What is Collegium Pharmaceutical Inc (COLL) fair value?
How does COLL's valuation metrics compare to the industry average?
What is the current P/B ratio for Collegium Pharmaceutical Inc (COLL) as of Dec 05 2025?
What is the current FCF Yield for Collegium Pharmaceutical Inc (COLL) as of Dec 05 2025?
What is the current Forward P/E ratio for Collegium Pharmaceutical Inc (COLL) as of Dec 05 2025?